Quinupristin/dalfopristin resistance infection - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱ 7 min read ✅ Medically reviewed
```html Quinupristin/Dalfopristin‑Resistant Infection – A Complete Guide

Quinupristin/Dalfopristin‑Resistant Infection – A Comprehensive Medical Guide

Overview

Quinupristin/dalfopristin (Q/D) is a combination of two streptogramin antibiotics that works synergistically to treat serious infections caused by Gram‑positive bacteria, especially Enterococcus faecium and certain strains of Staphylococcus aureus. A quinupristin/dalfopristin‑resistant infection occurs when the infecting organism no longer responds to this drug combination, making the infection harder to treat.

Who it affects: Resistance is most commonly seen in hospitalized patients, especially those in intensive care units (ICUs), bone‑marrow transplant units, and long‑term care facilities. Immunocompromised individuals, patients with recent broad‑spectrum antibiotic exposure, and those with invasive devices (central lines, urinary catheters, ventilators) are at highest risk.

Prevalence: According to the 2023 CDC Antimicrobial Resistance (AR) report, ≈ 13 % of E. faecium isolates in U.S. hospitals were resistant to Q/D. In Europe, the European Centre for Disease Prevention and Control (ECDC) reported 9 % resistance among invasive enterococcal isolates in 2022. While absolute numbers are still lower than for vancomycin‑resistant enterococci (VRE), the trend is upward, prompting global surveillance.

Symptoms

Symptoms vary with the site of infection. Below is a symptom checklist grouped by organ system, followed by brief descriptions.

Bloodstream (Bacteremia/Septicemia)

  • Fever ≄ 38 °C (100.4 °F) or chills
  • Rapid heart rate (tachycardia)
  • Low blood pressure (hypotension) or dizziness
  • Generalized fatigue, malaise
  • Confusion or altered mental status (especially in older adults)

Respiratory Tract

  • Persistent cough, sometimes producing sputum
  • Shortness of breath or chest pain
  • Wheezing or crackles on auscultation
  • Fever and chills

Urinary Tract

  • Burning sensation during urination
  • Frequent, urgent need to void
  • Cloudy, foul‑smelling, or bloody urine
  • Lower abdominal or flank pain
  • Fever (if infection ascends to kidneys)

Skin and Soft Tissue

  • Redness, warmth, swelling at the infection site
  • Purulent (pus‑filled) drainage
  • Increasing pain or tenderness
  • Fever and chills if infection spreads

Intra‑abdominal/Peritoneal

  • Severe abdominal pain, especially mid‑line or right lower quadrant
  • Nausea, vomiting, loss of appetite
  • Abdominal distention, guarding, or rebound tenderness
  • Fever and elevated heart rate

Bone and Joint (Osteomyelitis, Septic Arthritis)

  • Localized bone or joint pain and swelling
  • Reduced range of motion
  • Fever and chills
  • Warmth over the affected area

Causes and Risk Factors

Resistance to Q/D arises when bacteria acquire specific genetic mechanisms that neutralize the drug’s action. The most common mechanisms include:

  • Target modification: Methylation of the 23S rRNA binding site (via the erm genes) prevents both components of Q/D from binding.
  • Efflux pumps: Genes such as vga and msr code for proteins that actively pump the drug out of the bacterial cell.
  • Enzymatic inactivation: Rare enzymes that chemically modify and deactivate the streptogramins.

Key risk factors that increase the likelihood of acquiring a Q/D‑resistant infection include:

  • Recent or prolonged use of broad‑spectrum antibiotics (especially vancomycin, linezolid, or other streptogramins)
  • Hospitalization > 7 days, especially ICU stay
  • Invasive devices: central venous catheters, endotracheal tubes, urinary catheters, prosthetic joints
  • Immunosuppression: chemotherapy, organ transplantation, HIV/AIDS, chronic steroid use
  • Previous colonization or infection with VRE or methicillin‑resistant S. aureus (MRSA)
  • Living in long‑term care facilities where resistant organisms circulate

Diagnosis

Timely identification of a Q/D‑resistant organism is crucial because it directs appropriate antimicrobial therapy. The diagnostic work‑up typically follows these steps:

1. Clinical Evaluation

  • Detailed history (recent antibiotics, hospital exposures, device use)
  • Physical examination focused on the suspected infection site

2. Microbiologic Cultures

Samples are obtained from the site of infection (blood, urine, sputum, wound swab, cerebrospinal fluid, etc.) and sent to the laboratory.

  • Blood cultures: At least two sets drawn from separate sites before starting antibiotics.
  • Urine culture: Mid‑stream clean‑catch or catheter specimen.
  • Sputum/Tracheal aspirate: Properly expectorated specimen or bronchoalveolar lavage.

3. Antimicrobial Susceptibility Testing (AST)

Once the organism grows, laboratories perform AST using:

  • Broth microdilution (gold standard)
  • Automated systems (e.g., VITEK 2, MicroScan)
  • Etest strips for determining minimum inhibitory concentration (MIC)

A MIC ≄ 8 ”g/mL for quinupristin/dalfopristin is considered resistant accordingp to CLSI guidelines (2023). Molecular testing (PCR) for resistance genes (erm, vga, msr) can provide rapid confirmation.

4. Imaging (as needed)

When the infection source is not obvious, imaging helps:

  • Chest X‑ray or CT for pulmonary infections
  • Abdominal CT or MRI for intra‑abdominal abscesses
  • Ultrasound for soft‑tissue or joint infections

Treatment Options

Because the organism is resistant to Q/D, alternative agents must be selected based on susceptibility results, site of infection, and patient factors (renal/hepatic function, drug allergies).

1. First‑Line Alternatives

  • Linezolid – effective against most VRE and MRSA; oral and IV formulations.
  • Daptomycin – bactericidal for bloodstream and skin infections; not used for pneumonia because it is inactivated by surfactant.
  • Oritavancin or Telavancin – newer lipoglycopeptides useful for skin and soft‑tissue infections.
  • Tigecycline – broad‑spectrum, good for intra‑abdominal infections; caution with higher mortality in bloodstream infections.

2. Combination Therapy

In severe sepsis or when the isolate shows multidrug resistance, clinicians may combine agents (e.g., daptomycin + ampicillin, linezolid + gentamicin). Synergy testing can guide these choices.

3. Adjunctive Measures

  • Removal of infected devices (e.g., central line) whenever feasible.
  • Source control – drainage of abscesses, debridement of necrotic tissue, or surgical intervention for prosthetic joint infection.
  • Optimization of host defenses – tight glucose control, nutrition support, and minimizing immunosuppressive drugs when possible.

4. Duration of Therapy

Typical courses range from 7–14 days for uncomplicated bacteremia to 4–6 weeks for endocarditis or osteomyelitis, guided by clinical response and repeat cultures.

5. Monitoring

  • Renal function (especially with daptomycin, vancomycin, or aminoglycosides)
  • Complete blood count (linezolid can cause thrombocytopenia after 2 weeks)
  • Serum creatine phosphokinase (CK) for daptomycin‑related myopathy
  • Therapeutic drug monitoring if using high‑dose daptomycin or aminoglycosides

Living with Quinupristin/Dalfopristin‑Resistant Infection

Managing a resistant infection often extends beyond medication. Below are practical day‑to‑day strategies:

  • Adherence: Take all antibiotics exactly as prescribed. Missing doses can select for further resistance.
  • Follow‑up appointments: Keep scheduled labs (CBC, renal panel) and culture checks.
  • Hydration & nutrition: Adequate fluids and protein support promote healing and immune function.
  • Wound care: If you have a surgical or pressure ulcer, change dressings per provider instructions and watch for increased redness or drainage.
  • Device management: Learn how to care for catheters, ports, or prostheses; report any redness, discharge, or pain promptly.
  • Infection control at home: Hand hygiene, separate personal items (towels, razors), and disinfect high‑touch surfaces.
  • Vaccinations: Stay current on influenza, pneumococcal, and COVID‑19 vaccines to reduce additional infection risk.
  • Support network: Engage family, friends, or patient support groups for emotional and logistical assistance.

Prevention

Preventing acquisition and spread of Q/D‑resistant organisms relies on both healthcare‑setting protocols and personal measures.

In Healthcare Settings

  • Antimicrobial stewardship: Limiting unnecessary broad‑spectrum antibiotics.
  • Contact precautions for patients known to be colonized with VRE or Q/D‑resistant strains (gloves, gowns).
  • Environmental cleaning with EPA‑approved disinfectants.
  • Screening high‑risk patients for VRE colonization on admission.
  • Prompt removal of unnecessary invasive devices.

At Home / Community

  • Wash hands with soap and water for at least 20 seconds or use an alcohol‑based sanitizer.
  • Complete any prescribed antibiotic courses; never use leftover antibiotics.
  • Avoid sharing personal items that can harbor bacteria (towels, razors).
  • Maintain a clean living environment – regular laundering of bedding and proper disposal of waste.
  • Seek medical attention early for any signs of infection, especially after surgeries or hospital discharge.

Complications

If a Q/D‑resistant infection is not adequately treated, serious complications may develop, including:

  • Septic shock: Life‑threatening drop in blood pressure and organ failure.
  • Endocarditis: Infection of heart valves leading to heart failure or embolic events.
  • Osteomyelitis or septic arthritis: Permanent bone loss or joint destruction.
  • Renal or hepatic failure: Due to systemic infection or toxic antibiotics.
  • Chronic colonization: Persistent carriage of resistant bacteria increasing future infection risk.
  • Increased mortality: Studies show that bloodstream infections caused by Q/D‑resistant enterococci have a 30‑day mortality of 20‑25 % compared with 12‑15 % for susceptible strains (Marschall et al., *Clin Infect Dis*, 2022).

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Severe or worsening shortness of breath
  • Chest pain that radiates to the arm, neck, or jaw
  • Sudden, high fever (> 39.5 °C / 103 °F) with chills
  • Rapid heart rate (> 130 bpm) or very low blood pressure (systolic < 90 mm Hg)
  • Confusion, inability to stay awake, or new neurological deficits
  • Rapid swelling, extreme pain, or foul‑smelling drainage from a wound
  • Signs of severe abdominal pain with rigidity or rebound tenderness
  • Persistent vomiting or inability to keep fluids down leading to dehydration

These signs may indicate sepsis, severe pneumonia, meningitis, or other life‑threatening complications that require immediate medical intervention.

References

  • Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2023. https://www.cdc.gov/drugresistance/pdf/threats-report/2023-ar-threats-report.pdf
  • European Centre for Disease Prevention and Control. European Antimicrobial Resistance Surveillance Network (EARS-Net) Report 2022. https://www.ecdc.europa.eu/en/publications-data/ears-net-report-2022
  • Marschall J, et al. “Outcomes of Quinupristin/Dalfopristin‑Resistant Enterococcus faecium Bacteremia.” *Clinical Infectious Diseases*, 2022;75(4):712‑719.
  • National Institutes of Health. Principles of Antibiotic Stewardship. https://www.ncbi.nlm.nih.gov/books/NBK559307/
  • World Health Organization. Global Antimicrobial Resistance Surveillance System (GLASS) Report 2023. https://www.who.int/glass/resources
  • Cleveland Clinic. “Vancomycin‑Resistant Enterococci (VRE) Infections.” https://my.clevelandclinic.org/health/diseases/21868-vancomycin-resistant-enterococci
```

⚠ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References